Influence of endogenous opioids on the response of selected hormones to exercise in humans. 1986

P A Farrell, and A B Gustafson, and T L Garthwaite, and R K Kalkhoff, and A W Cowley, and W P Morgan

To examine the influence of endogenous opioids on the hormonal response to isotonic exercise, eight males were studied 2 h after oral administration of placebo or 50 mg naltrexone, a long-lasting opioid antagonist. Venous blood samples were obtained before, during, and after 30 min of bicycle exercise at 70% VO2max. Naltrexone had no effect on resting cardiovascular, endocrine, or serum variables. During exercise epinephrine was higher [mean 433 +/- 100 (SE) pg/ml] at 30 min with naltrexone than during placebo (207 +/- 26 pg/ml, P less than 0.05). Plasma norepinephrine showed the same trend but the difference (2,012 +/- 340 pg/ml with naltrexone and 1,562 +/- 241 pg/ml with placebo) was not significant. Plasma glucose was higher at all times with naltrexone. However, the difference was significant only 10 min into recovery from exercise (104.7 +/- 4.7 vs. 94.5 +/- 2.8 mg/dl). Plasma growth hormone and cortisol increased during recovery and these elevations were significantly (P less than 0.05) augmented by naltrexone. Plasma vasopressin and prolactin increased with exercise as did heart rate, blood pressure, lactic acid, and several serum components; these increases were not affected by naltrexone. Psychological tension or anxiety was lower after exercise compared with before and this improved psychological state was not influenced by the naltrexone treatment. These data suggest that exercise-induced activation of the endogenous opioid system may serve to regulate the secretion of several important hormones (i.e., epinephrine) during and after exercise.

UI MeSH Term Description Entries
D008297 Male Males
D009271 Naltrexone Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Antaxone,Celupan,EN-1639A,Nalorex,Naltrexone Hydrochloride,Nemexin,ReVia,Trexan,EN 1639A,EN1639A
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D004644 Emotions Those affective states which can be experienced and have arousing and motivational properties. Feelings,Regret,Emotion,Feeling,Regrets
D004723 Endorphins One of the three major groups of endogenous opioid peptides. They are large peptides derived from the PRO-OPIOMELANOCORTIN precursor. The known members of this group are alpha-, beta-, and gamma-endorphin. The term endorphin is also sometimes used to refer to all opioid peptides, but the narrower sense is used here; OPIOID PEPTIDES is used for the broader group. Endorphin
D005082 Physical Exertion Expenditure of energy during PHYSICAL ACTIVITY. Intensity of exertion may be measured by rate of OXYGEN CONSUMPTION; HEAT produced, or HEART RATE. Perceived exertion, a psychological measure of exertion, is included. Physical Effort,Effort, Physical,Efforts, Physical,Exertion, Physical,Exertions, Physical,Physical Efforts,Physical Exertions
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol

Related Publications

P A Farrell, and A B Gustafson, and T L Garthwaite, and R K Kalkhoff, and A W Cowley, and W P Morgan
April 2021, Psychoneuroendocrinology,
P A Farrell, and A B Gustafson, and T L Garthwaite, and R K Kalkhoff, and A W Cowley, and W P Morgan
December 1981, The New England journal of medicine,
P A Farrell, and A B Gustafson, and T L Garthwaite, and R K Kalkhoff, and A W Cowley, and W P Morgan
January 1989, European journal of applied physiology and occupational physiology,
P A Farrell, and A B Gustafson, and T L Garthwaite, and R K Kalkhoff, and A W Cowley, and W P Morgan
August 2017, The Journal of neuroscience : the official journal of the Society for Neuroscience,
P A Farrell, and A B Gustafson, and T L Garthwaite, and R K Kalkhoff, and A W Cowley, and W P Morgan
December 2021, Pain,
P A Farrell, and A B Gustafson, and T L Garthwaite, and R K Kalkhoff, and A W Cowley, and W P Morgan
January 1983, Hypertension (Dallas, Tex. : 1979),
P A Farrell, and A B Gustafson, and T L Garthwaite, and R K Kalkhoff, and A W Cowley, and W P Morgan
May 1985, Journal of applied physiology (Bethesda, Md. : 1985),
P A Farrell, and A B Gustafson, and T L Garthwaite, and R K Kalkhoff, and A W Cowley, and W P Morgan
April 1985, The American review of respiratory disease,
P A Farrell, and A B Gustafson, and T L Garthwaite, and R K Kalkhoff, and A W Cowley, and W P Morgan
May 1986, Thorax,
P A Farrell, and A B Gustafson, and T L Garthwaite, and R K Kalkhoff, and A W Cowley, and W P Morgan
May 2017, Nature communications,
Copied contents to your clipboard!